Issue navigation
Volume 188, Issue Supplement_3, June 2023
Revolutionizing Atopic Dermatitis April 29–May 1, 2023
Abstracts
365 Phase 2 trial in progress—lirentelimab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.001, https://doi.org/10.1093/bjd/ljad162.001
368 Impact of a digital atopic dermatitis educational intervention on Hispanic patients and family members
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.002, https://doi.org/10.1093/bjd/ljad162.002
372 Early insights into the characteristics of tralokinumab patients in a real-world setting in the United States
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.003, https://doi.org/10.1093/bjd/ljad162.003
373 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.004, https://doi.org/10.1093/bjd/ljad162.004
374 Shared decision making for eczema patients and caregivers is not dependent on length of relationship with a provider or provider specialty
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.005, https://doi.org/10.1093/bjd/ljad162.005
375 Understanding the effectiveness, utilization and perceptions of action plans in adults and caregivers of children with atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.006, https://doi.org/10.1093/bjd/ljad162.006
377 Real-world use of OPZELURA™: safety analysis at 1 year
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.007, https://doi.org/10.1093/bjd/ljad162.007
380 Patients maintain stable response with no or minimal fluctuations during treatment with lebrikizumab up to Week 52
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.008, https://doi.org/10.1093/bjd/ljad162.008
381 Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.009, https://doi.org/10.1093/bjd/ljad162.009
382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.010, https://doi.org/10.1093/bjd/ljad162.010
383 Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.011, https://doi.org/10.1093/bjd/ljad162.011
384 Ruxolitinib 1.5% cream efficacy data for moderate-to-severe chronic hand dermatitis: open-label trial 4-weeks interim analysis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.012, https://doi.org/10.1093/bjd/ljad162.012
386 Complete/near-complete itch response observed in adult and adolescent patients with moderate-to-severe atopic dermatitis initiating dupilumab treatment in real-world practice
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.013, https://doi.org/10.1093/bjd/ljad162.013
388 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.014, https://doi.org/10.1093/bjd/ljad162.014
389 A CME virtual patient simulation activity evaluated the management of adults with atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.015, https://doi.org/10.1093/bjd/ljad162.015
390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.016, https://doi.org/10.1093/bjd/ljad162.016
392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.017, https://doi.org/10.1093/bjd/ljad162.017
393 Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.018, https://doi.org/10.1093/bjd/ljad162.018
394 Gene expression based molecular test proves clinical validity as diagnostic aid for the differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded tissue
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.019, https://doi.org/10.1093/bjd/ljad162.019
395 Assessing imputation methods with the lebrikizumab clinical trial program
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.020, https://doi.org/10.1093/bjd/ljad162.020
396 Rapid, substantial and sustained reduction of itch in adults with atopic dermatitis applying ruxolitinib cream 1.5% (SCRATCH-AD)
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.021, https://doi.org/10.1093/bjd/ljad162.021
399 Pooled safety analysis of lebrikizumab in patients with uncontrolled asthma from three randomized clinical trials
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.022, https://doi.org/10.1093/bjd/ljad162.022
400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.023, https://doi.org/10.1093/bjd/ljad162.023
401 Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.024, https://doi.org/10.1093/bjd/ljad162.024
402 Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.025, https://doi.org/10.1093/bjd/ljad162.025
403 Achievement of minimal disease activity is associated with improvements in symptoms, quality of life and treatment satisfaction in patients with atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.026, https://doi.org/10.1093/bjd/ljad162.026
405 Understanding patient experience and factors influencing patient preference in the treatment of moderate-to-severe atopic dermatitis through in-depth qualitative patient interviews
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.027, https://doi.org/10.1093/bjd/ljad162.027
406 Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.028, https://doi.org/10.1093/bjd/ljad162.028
408 Dupilumab treatment in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.029, https://doi.org/10.1093/bjd/ljad162.029
409 Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.030, https://doi.org/10.1093/bjd/ljad162.030
410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.031, https://doi.org/10.1093/bjd/ljad162.031
411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.032, https://doi.org/10.1093/bjd/ljad162.032
413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.033, https://doi.org/10.1093/bjd/ljad162.033
414 Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.034, https://doi.org/10.1093/bjd/ljad162.034
415 Efficacy of 2% crisaborole ointment in 49 patients of atopic dermatitis with chronic hyperplasia lesions: a real-world study
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.035, https://doi.org/10.1093/bjd/ljad162.035
416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.036, https://doi.org/10.1093/bjd/ljad162.036
417 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.037, https://doi.org/10.1093/bjd/ljad162.037
418 A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.038, https://doi.org/10.1093/bjd/ljad162.038
419 Patient satisfaction with treatments for moderate-to-severe atopic dermatitis according to degree and speed of skin and itch improvements: results from a patient survey in the United States
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.039, https://doi.org/10.1093/bjd/ljad162.039
420 Molecular assessment of atopic dermatitis and psoriasis samples collected using a noninvasive technique
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.040, https://doi.org/10.1093/bjd/ljad162.040
421 The role of itch resolution and skin clearance in patient-reported atopic dermatitis severity and quality of life: real-world insights from TARGET-DERM AD
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.041, https://doi.org/10.1093/bjd/ljad162.041
422 Healthcare disparities in atopic dermatitis: insights from TARGET-DERM registry
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.042, https://doi.org/10.1093/bjd/ljad162.042
423 Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.043, https://doi.org/10.1093/bjd/ljad162.043
424 Effect of abrocitinib vs. dupilumab on skin pain: an analysis of the phase 3 JADE COMPARE and JADE DARE trials
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.044, https://doi.org/10.1093/bjd/ljad162.044
425 Effect of upadacitinib on SCORAD intensity items: analysis from the Measure Up 1 and Measure Up 2 studies
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.045, https://doi.org/10.1093/bjd/ljad162.045
426 Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.046, https://doi.org/10.1093/bjd/ljad162.046
427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.047, https://doi.org/10.1093/bjd/ljad162.047
428 Evaluating chronic pruritus prevalence, characteristics and effects on atopic dermatitis patients from a referral university hospital in São Paulo, Brazil: a cross-sectional study
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.048, https://doi.org/10.1093/bjd/ljad162.048
429 Differentiation of IL-22 levels in inflammatory diseases using a high sensitivity ELISA
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.049, https://doi.org/10.1093/bjd/ljad162.049
430 Comparison of effectiveness of topical treatments for atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.050, https://doi.org/10.1093/bjd/ljad162.050
431 Assessment of racial and ethnic differences of atopic dermatitis severity and treatment patterns in a diverse outpatient cohort in the United States
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.051, https://doi.org/10.1093/bjd/ljad162.051
432 Comparative treatment persistence of different advanced-therapies in patients with atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.052, https://doi.org/10.1093/bjd/ljad162.052
433 Outcome measures demographics and characteristics in predicting hand eczema severity in atopic dermatitis patients
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.053, https://doi.org/10.1093/bjd/ljad162.053
434 Efficacy and safety of crisaborole ointment, 2%, in Chinese and Japanese pediatric patients aged 2–17 years with mild-to-moderate atopic dermatitis
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.054, https://doi.org/10.1093/bjd/ljad162.054
435 Burden of disease and unmet needs in the diagnosis and management of atopic dermatitis in the Middle East
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.055, https://doi.org/10.1093/bjd/ljad162.055
436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.056, https://doi.org/10.1093/bjd/ljad162.056
437 Treatment-emergent adverse events in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis treated with dupilumab in an open-label extension clinical trial
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.057, https://doi.org/10.1093/bjd/ljad162.057
438 Potentially greater efficacy with CBP-201 for adults with severe vs. moderate atopic dermatitis at baseline: subgroup analyses from the WW001 phase 2 randomized trial
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.058, https://doi.org/10.1093/bjd/ljad162.058
439 Patients with mild to moderate atopic dermatitis: a first-in-human, open-label, dose-escalating, nonrandomized clinical trial with AMTX-100
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.059, https://doi.org/10.1093/bjd/ljad162.059
440 Prevalence and burden of rhinoconjunctivitis in atopic dermatitis patients: a cross-sectional study
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.060, https://doi.org/10.1093/bjd/ljad162.060
